The University of Southampton
University of Southampton Institutional Repository

Causal relationship between key genes and metabolic dysfunction-associated fatty liver disease risk mediated by immune cells: A Mendelian randomization and mediation analysis

Causal relationship between key genes and metabolic dysfunction-associated fatty liver disease risk mediated by immune cells: A Mendelian randomization and mediation analysis
Causal relationship between key genes and metabolic dysfunction-associated fatty liver disease risk mediated by immune cells: A Mendelian randomization and mediation analysis
Aim: non-invasive diagnostics for metabolic dysfunction–associated fatty liver disease (MAFLD) remain challenging. We aimed to identify novel key genes as non-invasive biomarkers for MAFLD, elucidate causal relationships between biomarkers and MAFLD and determine the role of immune cells as potential mediators.

Materials and methods: utilizing published transcriptome data of patients with biopsy-proven MAFLD, we applied linear models for microarray data, least absolute shrinkage and selector operation (LASSO) regressions and receiver operating characteristic (ROC) curve analyses to identify and validate biomarkers for MAFLD. Using the expression quantitative trait loci database and a cohort of 778 614 Europeans, we used Mendelian randomization to analyse the causal relationships between key biomarkers and MAFLD. Additionally, mediation analysis was performed to examine the involvement of 731 immunophenotypes in these relationships.

Results: We identified 31 differentially expressed genes, and LASSO regression showed three hub genes, IGFBP2, PEG10, and P4HA1, with area under the receiver operating characteristic (AUROC) curve of 0.807, 0.772 and 0.791, respectively, for identifying MAFLD. The model of these three genes had an AUROC of 0.959 and 0.800 in the development and validation data sets, respectively. This model was also validated using serum-based enzyme-linked immunosorbent assay data from MAFLD patients and control subjects (AUROC: 0.819, 95% confidence interval: 0.736–0.902). PEG10 was associated with an increased MAFLD risk (odds ratio = 1.106, p = 0.032) via inverse variance–weighted analysis, and about 30% of this risk was mediated by the percentage of CD11c + CD62L– monocytes.

Conclusions: the MAFLD panels have good diagnostic accuracy, and the causal link between PEG10 and MAFLD was mediated by the percentage of CD11c + CD62L– monocytes.

Mendelian randomization, diagnostic markers, mediation analysis, metabolic dysfunction–associated fatty liver disease
1462-8902
5590-5599
Feng, Gong
eb2cd086-901d-4950-8fbe-e7e262bc8da3
He, Na
8f8d16d2-1d22-4aca-911b-0cc231806003
Gao, Jing
16aebd4f-40ce-421b-85e1-8a1724e6b47b
Li, Xiao-Cheng
108120a5-8310-4234-a17f-55282d4a6faf
Zhang, Fen-Na
0dec5b36-b0ed-4676-ace4-d53a6c46cafe
Liu, Cheng-Cheng
b55bda5c-4d20-410e-b14f-bc01db5b4206
Targher, Giovanni
59b2868f-d612-4171-b1df-30448c35ae1d
Byrne, Chrisopher D.
1370b997-cead-4229-83a7-53301ed2a43c
Mi, Man
a0751411-6764-417a-aa33-8d2d46a2a4f4
Zheng, Ming-Hua
56c24dc2-bb08-47b1-8736-b41fcad338e4
Ye, Feng
bfb1e5b8-a561-4059-be84-be8d55aefdd3
Feng, Gong
eb2cd086-901d-4950-8fbe-e7e262bc8da3
He, Na
8f8d16d2-1d22-4aca-911b-0cc231806003
Gao, Jing
16aebd4f-40ce-421b-85e1-8a1724e6b47b
Li, Xiao-Cheng
108120a5-8310-4234-a17f-55282d4a6faf
Zhang, Fen-Na
0dec5b36-b0ed-4676-ace4-d53a6c46cafe
Liu, Cheng-Cheng
b55bda5c-4d20-410e-b14f-bc01db5b4206
Targher, Giovanni
59b2868f-d612-4171-b1df-30448c35ae1d
Byrne, Chrisopher D.
1370b997-cead-4229-83a7-53301ed2a43c
Mi, Man
a0751411-6764-417a-aa33-8d2d46a2a4f4
Zheng, Ming-Hua
56c24dc2-bb08-47b1-8736-b41fcad338e4
Ye, Feng
bfb1e5b8-a561-4059-be84-be8d55aefdd3

Feng, Gong, He, Na, Gao, Jing, Li, Xiao-Cheng, Zhang, Fen-Na, Liu, Cheng-Cheng, Targher, Giovanni, Byrne, Chrisopher D., Mi, Man, Zheng, Ming-Hua and Ye, Feng (2024) Causal relationship between key genes and metabolic dysfunction-associated fatty liver disease risk mediated by immune cells: A Mendelian randomization and mediation analysis. Diabetes, Obesity and Metabolism, 26 (12), 5590-5599. (doi:10.1111/dom.15925).

Record type: Article

Abstract

Aim: non-invasive diagnostics for metabolic dysfunction–associated fatty liver disease (MAFLD) remain challenging. We aimed to identify novel key genes as non-invasive biomarkers for MAFLD, elucidate causal relationships between biomarkers and MAFLD and determine the role of immune cells as potential mediators.

Materials and methods: utilizing published transcriptome data of patients with biopsy-proven MAFLD, we applied linear models for microarray data, least absolute shrinkage and selector operation (LASSO) regressions and receiver operating characteristic (ROC) curve analyses to identify and validate biomarkers for MAFLD. Using the expression quantitative trait loci database and a cohort of 778 614 Europeans, we used Mendelian randomization to analyse the causal relationships between key biomarkers and MAFLD. Additionally, mediation analysis was performed to examine the involvement of 731 immunophenotypes in these relationships.

Results: We identified 31 differentially expressed genes, and LASSO regression showed three hub genes, IGFBP2, PEG10, and P4HA1, with area under the receiver operating characteristic (AUROC) curve of 0.807, 0.772 and 0.791, respectively, for identifying MAFLD. The model of these three genes had an AUROC of 0.959 and 0.800 in the development and validation data sets, respectively. This model was also validated using serum-based enzyme-linked immunosorbent assay data from MAFLD patients and control subjects (AUROC: 0.819, 95% confidence interval: 0.736–0.902). PEG10 was associated with an increased MAFLD risk (odds ratio = 1.106, p = 0.032) via inverse variance–weighted analysis, and about 30% of this risk was mediated by the percentage of CD11c + CD62L– monocytes.

Conclusions: the MAFLD panels have good diagnostic accuracy, and the causal link between PEG10 and MAFLD was mediated by the percentage of CD11c + CD62L– monocytes.

Text
Accept_20240820 - Accepted Manuscript
Restricted to Repository staff only until 4 September 2025.
Request a copy
Text
eDiscussion 1 - Accepted Manuscript
Restricted to Repository staff only until 4 September 2025.
Request a copy
Text
eMethod 1 - Accepted Manuscript
Restricted to Repository staff only until 4 September 2025.
Request a copy
Text
eMethod 2 - Accepted Manuscript
Restricted to Repository staff only until 22 August 2025.
Request a copy
Text
eMethod 3. - Accepted Manuscript
Restricted to Repository staff only until 22 August 2025.
Request a copy
Text
eMethod 4 - Accepted Manuscript
Restricted to Repository staff only until 22 August 2025.
Request a copy
Text
eResult 1 - Accepted Manuscript
Restricted to Repository staff only until 22 August 2025.
Request a copy
Text
eResult 2 - Accepted Manuscript
Restricted to Repository staff only until 22 August 2025.
Request a copy
Text
Figure 1 - Accepted Manuscript
Restricted to Repository staff only until 22 August 2025.
Request a copy
Text
Figure 2 - Accepted Manuscript
Restricted to Repository staff only until 22 August 2025.
Request a copy
Text
Figure 3 - Accepted Manuscript
Restricted to Repository staff only until 22 August 2025.
Request a copy
Text
Figure 4 - Accepted Manuscript
Restricted to Repository staff only until 22 August 2025.
Request a copy
Text
Supplementary Figure 1 - Accepted Manuscript
Restricted to Repository staff only until 22 August 2025.
Request a copy
Text
Supplementary Figure 2 - Accepted Manuscript
Restricted to Repository staff only until 22 August 2025.
Request a copy
Text
Supplementary Figure 3 - Accepted Manuscript
Restricted to Repository staff only until 22 August 2025.
Request a copy
Text
Supplementary Figure 4 - Accepted Manuscript
Restricted to Repository staff only until 22 August 2025.
Request a copy
Text
Supplementary Figure 5 - Accepted Manuscript
Restricted to Repository staff only until 22 August 2025.
Request a copy
Text
Supplementary Figure 6 - Accepted Manuscript
Restricted to Repository staff only until 22 August 2025.
Request a copy
Text
Supplementary Figure 7 - Accepted Manuscript
Restricted to Repository staff only until 22 August 2025.
Request a copy
Text
Supplementary Figure 8 - Accepted Manuscript
Restricted to Repository staff only until 22 August 2025.
Request a copy
Text
Supplementary Figure 9 - Accepted Manuscript
Restricted to Repository staff only until 22 August 2025.
Request a copy
Text
Supplementary Figure 10 - Accepted Manuscript
Restricted to Repository staff only until 22 August 2025.
Request a copy
Text
Supplementary Table 1 - Accepted Manuscript
Restricted to Repository staff only until 22 August 2025.
Request a copy
Text
Supplementary Table 2 - Accepted Manuscript
Restricted to Repository staff only until 22 August 2025.
Request a copy
Text
Supplementary Table 3 - Accepted Manuscript
Restricted to Repository staff only until 22 August 2025.
Request a copy
Text
Supplementary Table 4 - Accepted Manuscript
Restricted to Repository staff only until 22 August 2025.
Request a copy

Show all 26 downloads.

More information

Accepted/In Press date: 19 August 2024
e-pub ahead of print date: 4 September 2024
Published date: 4 September 2024
Additional Information: Publisher Copyright: © 2024 John Wiley & Sons Ltd.
Keywords: Mendelian randomization, diagnostic markers, mediation analysis, metabolic dysfunction–associated fatty liver disease

Identifiers

Local EPrints ID: 493813
URI: http://eprints.soton.ac.uk/id/eprint/493813
ISSN: 1462-8902
PURE UUID: d1c1ee0e-43ee-4a47-bdce-32634fa2ba9b
ORCID for Chrisopher D. Byrne: ORCID iD orcid.org/0000-0001-6322-7753

Catalogue record

Date deposited: 13 Sep 2024 16:32
Last modified: 16 Nov 2024 02:36

Export record

Altmetrics

Contributors

Author: Gong Feng
Author: Na He
Author: Jing Gao
Author: Xiao-Cheng Li
Author: Fen-Na Zhang
Author: Cheng-Cheng Liu
Author: Giovanni Targher
Author: Man Mi
Author: Ming-Hua Zheng
Author: Feng Ye

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×